276°
Posted 20 hours ago

XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

£9.9£99Clearance
ZTS2023's avatar
Shared by
ZTS2023
Joined in 2023
82
63

About this deal

B. Grube, et al., “A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study,” Obesity 21, 58–64 (2013). Our findings stand in line with results obtained by Wang et al., who demonstrated that okra intake decreased serum and hepatic total cholesterol and triglyceride levels, and enhanced fecal excretion of bile acids in mice [ 46]. In other study, Kahlon et al. showed that okra polysaccharides have strong bile acid binding properties [ 47]. Furthermore, Chen et al. reported that okra powder showed oil-binding capacities and cholesterol adsorption properties [ 48]. Additionally, results from animal study by Han et al. imply that inulin may also possess a fat-binding property besides its known beneficial effect as prebiotic, which contributed to a lower triglyceride and cholesterol levels in rats fed with high fat diet in the experiments [ 49]. Thus, the cholesterol-lowering effect of IQP-AE-103 could possibly be related to the physicochemical properties of both okra and inulin. No significant differences in changes of feeling of fullness and food cravings between the study arms were observed. However, feeling of hunger decreased in 66% of subjects in the high-dose group (statistically significant pre-post change). This may be related to the swelling property of okra pods reported earlier [ 22]. Okra constituents such as soluble fibre or polysaccharides may increase viscosity of taken meal and form a gel, thus increasing gastric distension and thereby promoting satiety [ 45]. Direct comparisons of IQP-AE-103 with other weight loss agents that affect dietary fat absorption such as chitosan, Litramine®, or orlistat are difficult for methodological reasons. Ho et al. reported that there were no significant changes from baseline in body weight after 12 weeks of treatment with chitosan [ 39]. A treatment with Litramine® (a proprietary fibre complex) led to 3.8 kg weight loss after 12 weeks of intake [ 17]. As for orlistat (gastric and pancreatic lipase inhibitor), a study by Anderson et al. reported a 3.05 kg weight loss in overweight subjects after 16 weeks of treatment at 180 mg per day [ 40], whereas at higher dose of 360 mg per day, it caused a body weight reduction of 8.3 kg after 12-week period in obese women [ 41].

Based on the physicochemical properties of okra pods and inulin, and the fat binding capacity shown in vitro, it was hypothesized that a product containing powdered okra pods and inulin could potentially contribute to weight loss. Hence, the primary objective of this randomised, double-blind, placebo-controlled clinical study was to evaluate the weight loss potential of IQP-AE-103 over the period of 12 weeks in overweight and moderately obese subjects. In this study, it was demonstrated that in conjunction with a hypocaloric diet, IQP-AE-103 at both low dose (990 mg okra and 255 mg inulin/day) and high dose (1980 mg okra and 510 mg inulin/day) causes significant weight loss and that the effects are greater than those in the placebo. Baseline body weight was reduced by 5.03 ± 2.50 kg in the high-dose group and by 3.01 ± 2.19 kg in the low-dose group, compared with 0.98 ± 2.06 kg in the placebo group. Also, for the high-dose group, weight loss effect due to IQP-AE-103 consumption was observed as early as at 2 weeks of treatment and was sustained over the course of the 12-week intake period. More importantly, the proportion of subjects who lost at least 5% of baseline body weight was 60.0% in the high-dose IQP-AE-103 group, a proportion that is significantly higher than that in the low-dose and the placebo groups. Such weight loss due to the intake of IQP-AE-103 is considered to be of clinical relevance as European Medicines Agency associates a weight loss of 5% or more with a decrease of disease risk factors associated with overweight and obesity [ 38]. Subgroup analysis showed that although both IQP-AE-103 high- and low-dose consumptions led to significant weight loss in overweight subjects, for moderately obese subjects, only high dose caused a significant body weight reduction. Subgroup analysis also showed a statistically significant weight loss in both high- and low-dose IQP-AE-103 groups in subjects aged 41–65 years when compared with placebo group, whereas only the high-dose group showed a significant weight loss versus placebo in subjects aged 18–40 years. B. Grube, et al., “IQP-VV-102, A Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety,” Evidence-Based Complementary and Alternative Medicine: http://dx.doi.org/10.1155/2015/413075 (2015).That is why I chose to have Trademark Elite to register the trademark for my award-winning law blog. Another finding of this study is that besides weight loss, IQP-AE-103 showed beneficial effects on lipid metabolism. A significantly higher proportion of subjects in the high-dose IQP-AE-103 group experienced a reduction in triglyceride levels at the end of the study compared with placebo. In subjects with higher baseline total cholesterol levels (>6.2 mmol/L), high dose of IQP-AE-103 was shown to significantly reduce total cholesterol and LDL-cholesterol (pre-post change). Therefore, current outcome suggests that long-term treatment with IQP-AE-103 could be beneficial for subjects with elevated blood lipid levels in reducing the risk of cardiovascular disease. Clinically proven efficacy: Promote weight loss through a reduced food consumption - prevent unnecessary snaking and hunger pangs

In this study, we investigated the efficacy and tolerability/safety of IQP-AE-103 for reducing body weight in overweight and obese subjects. 2. Materials and Methods 2.1. Participants XLS-Medical For the treatment and prevention of excess weight. Fight food cravings & cut portion sizes. 94% experinced a feeling of fullness.Stool frequency was assessed based on bowel movements recorded in the subject diaries 3 days a week. Physical activity was recorded using validated International Physical Activity Questionnaire, Short Form (IPAQ-SF) [ 36] during all study visits from visit 2 to visit 6. It is recommended to take other medications at least one hour before, or four hours after taking Hunger Buddy. Adjust dosage with reference to a healthcare professional. The incidence of adverse side effects being reported was very rare (0.01%). These hypersensitivity reactions were typical of food allergies, like rash, itching, slight swelling and mild gastrointestinal upset. In such cases, treatment should be discontinued. Hunger Buddy by XLS is a medical device. Only recommended for adults over 18 years of age. The use of this product by adolescents 12-18 years old is subject to the supervision of healthcare professionals. This product must be taken as a whole capsule with a full glass of water (approximately 250 ml). Do not open the capsule and avoid taking in powder form to avoid choking. Please read the enclosed product insert before use. It is recommended to drink at least 2 litres of water a day. Slight constipation could occur in case of limited liquid intake. Do not take during pregnancy or whilst breastfeeding, or if your BMI is below 18.5. Consult your healthcare professional before taking this product if you have any medical condition or if you are diabetic. Keep out of reach and sight of children. Please read the enclosed product insert before use. Product Specification The resulting plant-based compound reduces dietary fat absorption through gastrointestinal fat binding, and has been shown to bind dietary fat at a level previously only achieved by prescription drugs, but without the undesirable side-effects. 4

Responder rate for subjects who lost ≥3% and ≥5% of initial body weight at v6. LD = low dose; HD = high dose. a vs. placebo; b vs. placebo; c vs. low-dose group. Institute of Medicine, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients), The National Acadamy Press, Washington, DC, USA, 2005.

No, you don’t need to head to your computer to compress a PDF file. With PDF2Go you can do this - you guessed it - on the go. As demonstrated by Zaluvida Group’s research and evidenced in InQpharm’s three bmiSMART products, efficacious, safe and easy to apply approaches to weight management do exist. They also allow adaption to individual dietary habits (such as preference for fatty foods or carbohydrate-rich diets) and can help to overcome initial hunger sensations while individuals are transitioning to a healthier diet. InQpharm’s proprietary complex Tanitol is formulated with a unique blend of L-arabinose, a naturally occurring pentose, and grape marc extract. L-Arabinose works by inhibiting the hydrolysis of sugar (sucrose) to glucose and fructose by intestinal sucrase, thus reducing glucose absorption in the intestine. Hunger Buddy is clinically proven to promote significant weight loss through a reduced food intake. It is particularly suitable for those who constantly have a big appetite and cannot control portion size. Hunger Buddy is a certified medical device product for the treatment and

Hunger Buddy does not contain any ingredient of animal origin and has no added artificial, flavourings, salt or preservatives.For the treatment and prevention of excess weight. Fight food cravings & cut portion sizes. 94% experinced a feeling of fullness. Safety evaluation included measurement of laboratory parameters (full blood count, clinical chemistry, liver and renal functions and fat-soluble vitamins (A, D, E, and K) levels) and urine analysis at visit 1 and visit 6, as well as assessment of vital signs during each visit. Adverse events were recorded, regardless of causality at every visit. Global evaluation of tolerability by subjects and investigators was performed at the end of the study. The mean reduction in waist circumference was more pronounced in both IQP-AE-103 groups, compared with that in the placebo group at the end of the study. Subjects in the high-dose IQP-AE-103 arm had a mean reduction in waist circumference of 4.1 ± 3.3 cm, whereas the mean reduction in the low-dose IQP-AE-103 arm was 2.5 ± 2.4 cm, in contrast to only 0.9 ± 1.6 cm reported in the placebo group ( and versus placebo, respectively). Also, there were statistically significant differences in the percentage of subjects with reduction in hip circumference between the study groups at week 12, between high-dose IQP-AE-103 and the placebo group (91.4% vs. 54.8%; ), as well as between low-dose IQP-AE-103 and placebo groups (80% vs. 54.8%; ), however, not between low- and high-dose IQP-AE-103 groups ( ). No statistically significant differences in waist-to-hip ratio between the study groups were reported at week 12.

Asda Great Deal

Free UK shipping. 15 day free returns.
Community Updates
*So you can easily identify outgoing links on our site, we've marked them with an "*" symbol. Links on our site are monetised, but this never affects which deals get posted. Find more info in our FAQs and About Us page.
New Comment